A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

por Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Publicado 2015

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration...

por Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marschall, P., Veh, R. W., Bachmann, S., Deiana, S., Moreau, P.-H., Davidson, K., Harrington, K. A., Rickard, J. E., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, C. M., Harrington, C. R., Riedel, G., Theuring, F.
Publicado 2014